论文部分内容阅读
目的探讨异丙托溴铵联合糖皮质激素治疗慢性阻塞性肺疾病急性加重期的临床疗效。方法选取2015年1月—2016年1月于无锡市锡山人民医院治疗的慢性阻塞性肺疾病急性加重期患者88例,按照随机数字表法分为对照组与观察组,各44例。对照组患者给予异丙托溴铵药物治疗,观察组患者给予异丙托溴铵联合糖皮质激素治疗。比较两组患者临床疗效、肺功能〔用力肺活量(FVC)、第1秒用力呼气末容积(FEV1)〕及不良反应发生情况。结果观察组患者总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者FVC、FEV1比较,差异无统计学意义(P>0.05);治疗后观察组患者FVC、FEV1高于对照组,差异有统计学意义(P<0.05)。两组患者均无不良反应出现。结论糖皮质激素联合异丙托溴铵治疗慢性阻塞性肺疾病急性加重期的临床疗效显著,能有效改善患者肺功能。
Objective To investigate the clinical efficacy of ipratropium bromide combined with glucocorticoid in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods From January 2015 to January 2016, 88 patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) treated in Wuxi Xishan People’s Hospital were enrolled and divided into control group and observation group according to random number table. Patients in the control group were treated with ipratropium bromide, and patients in the observation group were treated with ipratropium bromide in combination with glucocorticoid. The clinical efficacy, pulmonary function (forced vital capacity (FVC), forced end-expiratory volume in one second (FEV1)] and incidence of adverse reactions were compared between the two groups. Results The total effective rate of observation group was higher than that of control group, the difference was statistically significant (P <0.05). There was no significant difference in FVC and FEV1 between the two groups before treatment (P> 0.05). After treatment, the FVC and FEV1 in the observation group were higher than those in the control group, the difference was statistically significant (P <0.05). No adverse reactions occurred in both groups. Conclusion The clinical efficacy of glucocorticoids combined with ipratropium bromide in the treatment of acute exacerbation of chronic obstructive pulmonary disease is significant, which can effectively improve pulmonary function.